Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 6, 2014 (12 years ago)

Vancomycin Hydrochloride for Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Temperature Abuse: Products experienced uncontrolled temperature excursions during transit.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Vancomycin Hydrochloride for Injection, USP, 500 mg Sterile Powder per Fliptop Vial, packaged in 10 Units per carton, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-4332-01.

Affected NDC 0409-4332-01

Compare with the code on your package — it is the most precise check available.

Drug: Vancomycin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Vancomycin Hydrochloride
NDC 00409-4332
500 mg/1 Injection, Powder, Lyophilized, for Solution
Intravenous
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
0409-4332-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0387-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Vancomycin recalls

See all
Class II · Moderate risk

Vancomycin HCL

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Ongoing Sterility / contamination Fagron Compounding Services NDC 71266-5082-01 D-0442-2026
Class II · Moderate risk

Vancomycin HCI

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Ongoing Sterility / contamination Fagron Compounding Services NDC 71266-5085-01 D-0441-2026
Class II · Moderate risk

Vancomycin HCI

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Ongoing Sterility / contamination Fagron Compounding Services NDC 71266-5083-01 D-0440-2026

Other recalls by Hospira Inc.

All 2014 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016